Sartar’s novel anti-GIST product
Chairman of the Board. Adjunct Professor of Cancer Biology, whose research focuses on rare cancers.
Professor of Oncology and the European key opinion leader of GIST therapies.
Ph.D. student, whose research focus is on new therapeutic targets in GIST.
An innovative Professor of Molecular Precision Medicine.
CEO of Herantis Pharma.
Upcoming events and news
Sartar strengthens the board of directors. CEO of Herantis Pharma, Pekka Simula, has been appointed as a new member to the Sartar Therapeutics board of directors.
Sartar will pitch at BioInvestor Forum and Global SPARK Showcase events. Meet us there! https://www.bio.org/events/bio-investor-forum https://www.bio.org/events/bio-investor-forum/spark-showcase
Meet us at the Anglonordic Life Science Conference in London. http://anglonordic.biopartnering.co.uk/
Sartar will pitch at the Life Sciences Venture Market 2018! http://www.stiftung-charite.de/en/events/charite-entrepreneurship-summit.html
Sartar will give a presentation at the 2nd KYOTO−SPARK Symposium. http://www.kyoto-spark.med.kyoto-u.ac.jp/newsen/20171227161216/
The Vice-Chairman of the Board and a co-founder the Sartar Therapeutics Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation. Congratulations Heikki on your new appointment!